A revised international staging system (R-ISS) from the IMWG provides the most up-to-date tool for stratifying patient risk based on prognosis. 

The Durie-Salmon Staging System is another staging system that correlates the amount of myeloma to the damage it has caused, such as bone disease or anemia.

Treatment Response

Careful testing after each cycle of treatment will indicate whether the treatment is working or not. If response is slow and side-effects are manageable, additional therapy should be considered. Thus, accurate response assessment is important. As shown below, there is a correlation between test results and the number of myeloma cells. 

IMWG response criteria - if the response is less than desired, the practitioner and patient should discuss whether to watch and wait, switch therapies, or continue with a maintenance dose.

Related Content

The Advanced Practitioner's Guide to Multiple Myeloma
JADPRO Vol. 7 | Supplement 1 | March 2016
Updates in the Diagnosis and Monitoring of Multiple Myeloma

Comprised of oncology-certified nurses, the Nurse Leadership Board has extensive knowledge of the multiple myeloma treatment and care landscape. These resources were developed by their team.

Last Medical Review: August 1, 2019

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.